Novo Nordisk is awaiting an FDA decision for their fixed-dose combination of the amylin receptor agonist, cagrilintide, and the GLP-1, semaglutide
Obesity and T2D are also associated with binge-eating disorder (BED)
By the second half of 2027 to mid-2028, we'll know whether the FDA agrees the efficacy justifies the tolerability trade-offs
OstroVit CLA + green tea + L-carnitine is a high-quality dietary supplement that is a source of conjugated linoleic acid, as well as green tea leaf extract and L-carnitine
In 2022, SAR441255 (GLP-1/GIP/glucagon receptor triagonist) was administered to obese, diabetic primates and healthy lean to overweight humans without diabetes
For patients whose primary goal is significant weight loss, Ozempic-class medications consistently outperform SGLT2 inhibitors